Prognostic Importance Of Teratoma At Time Of PC-RPLND For Patients With Metastatic Mixed Non-Seminomatous Germ Cell Tumors

Main Category: Urology / Nephrology
Also Included In: Cancer / Oncology
Article Date: 15 Jun 2008 - 2:00 PDT

email to a friend   printer friendly   opinions  

ORLANDO, FL (UroToday.com) - It is estimated that pathologic examination following post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) will reveal teratoma in approximately 40% of cases.

Svatek and colleagues identified 98 such patients that were found to have teratoma (+/- fibrosis) following PC-RPLND. 20% of patients developed disease recurrence and 9% died from testis cancer at a median follow-up of 41 months. Patients at highest risk of disease recurrence were found to be in a higher International Germ Cell Consensus Classification (IGCCC) risk category and had longer length of follow up.

Pre-operative serum HCG and amounts of pre-operative chemotherapy were predictive of disease-specific survival.

This report illustrates the fact that patients who have no viable tumor in the PC-RPLND specimen continue to be at very high risk for disease recurrence.

Presented by Robert S Svatek, MD, et al., at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.

Reported by UroToday.com Contributing Editor Alexander Kutikov, MD

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2008 - UroToday

• Additional
• References
• Citations